Additional Information

Dr. Elisaveta Voynova received her Ph.D. in Immunology from the Bulgarian Academy of Science.  In 2015, she completed her postdoctoral training at Autoimmunity and Functional Genomics Section, NIAID, after which, she joined a preclinical drug development group (R&D) at AstraZeneca.  In 2020, Dr Voynova joined the NCI’s T-cell Engineering Facility, where she developed a CAR-NK cell platform for pre-clinical treatment of T cell malignancies. Today, Dr Voynova manages the immunophenotyping unit of the NCI’s Clinical Research Correlatives Core, asssiting CCR’s clinical investigtors with her expertise in translational research and spectral flowcytometry. Her scientific focus includes cancer, autoimmunity, and inflammation.  

Scientific Publications:

https://pubmed.ncbi.nlm.nih.gov/?term=elisaveta+voynova&sort=date

https://scholar.google.com/citations?user=cgh0SnkAAAAJ&hl=en